Physician profile
Robert Feinfield
NPI 1013900182
$6,987.37
in general payments reported to CMS, 2019-2025
27 companies · $1,635 in 2025
The $1,635 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $214 · 2021: $205 · 2022: $398 · 2023: $2,825 · 2024: $1,195 · 2025: $1,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,610 · Travel and Lodging: $24.00 · Entertainment: $21.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,610.06 |
| Travel and Lodging | $24.00 |
| Entertainment | $21.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,625.06 | 2019-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| Glaukos Corporation | $1,867.27 | 2023-2025 | Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem, Ce-Marked Kxla System |
| Sun Pharmaceutical Industries INC. | $398.55 | 2019-2025 | Cequa |
| Dompe US, INC. | $237.26 | 2021-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $154.82 | 2019-2021 | |
| Rxsight INC | $145.78 | 2022-2023 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Eyevance Pharmaceuticals LLC | $144.23 | 2019-2022 | |
| Abbvie INC. | $131.46 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $131.33 | 2024-2025 | Xdemvy |
| Optos, INC. | $121.36 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $114.85 | 2022-2025 | Miebo, Envista Mx60 Iol, Vyzulta |
| Allergan, INC. | $110.14 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $109.79 | 2023 | Tecnis Iol |
| Amgen INC. | $109.66 | 2024-2025 | Tepezza |
| New World Medical,INC. | $101.01 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $79.03 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $73.51 | 2022-2024 | Tyrvaya |
| Carl Zeiss Meditec USA, INC. | $52.84 | 2023 | Visumax |
| Aerie Pharmaceuticals, INC. | $52.37 | 2020-2021 | |
| Horizon Therapeutics Plc | $48.06 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.28 | 2019-2020 | |
| Coopervision INC. | $31.65 | 2021 | |
| Rayner Intraocular Lenses Limited | $25.96 | 2024 | Omidria, Rayone Emv, Rayone Aspheric |
| Mallinckrodt Enterprises LLC | $23.17 | 2019 | |
| Kala Pharmaceuticals, INC. | $21.95 | 2019 | |
| Stryker Corporation | $20.39 | 2019 | |
| Galderma Laboratories, L.P. | $14.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Feinfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.